Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.

Supachaya SriphoosanaphanWitthawat PantumongkolWantanee KulpengChanchai CharonpongsuntornTawesak TanwandeeWattana SukeepaisarnjaroenAbhasnee Sobhonslidsuk Pisit Tangkijvanich

Published in: PloS one (2024)

Although A+B yielded the highest clinical benefit compared with BSC for the treatment of uHCC patients, A+B is not cost-effective in Thailand at the current price and poses budgetary challenges.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
squamous cell carcinoma
radiation therapy
liver metastases
metastatic colorectal cancer